Orum Therapeutics, Inc. (KOSDAQ:475830)
South Korea flag South Korea · Delayed Price · Currency is KRW
65,900
-5,100 (-7.18%)
Aug 12, 2026, 3:30 PM KST

Orum Therapeutics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
20.6123.5620,906135,41875.92
Revenue Growth
-99.90%-99.89%-84.56%178270.49%-
Gross Profit
20.1823.3120,904135,41875.09
Operating Income
-60,265-51,759-8,33595,607-43,648
Net Income
-48,646-41,969-5,74068,217-63,319
Earnings Per Share
-2263.64-2016.61-424.005646.14-13764.93
EPS Growth
-----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
274,230132,602118,799126,65812,085
Total Debt
26,61425,49828,33025,8792,589
Net Cash (Debt)
247,616107,10390,469100,7799,496
Net Cash Growth
87.94%18.39%-10.23%961.28%-
Net Cash Per Share
11522.385146.286682.586693.642064.33

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-44,015-35,989-11,28294,244-41,092
Capital Expenditures
-669.18-696.27-1,264-1,126-796.13
Free Cash Flow
-44,684-36,685-12,54593,117-41,888
Free Cash Flow Growth
-----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
97.93%98.91%99.99%100.00%98.91%
Operating Margin
-292397.83%-219651.47%-39.87%70.60%-57492.65%
Pretax Margin
-246612.43%-187369.48%-25.42%50.14%-83105.78%
Profit Margin
-236020.84%-178105.43%-27.46%50.38%-83402.60%
FCF Margin
-216801.46%-155680.70%-60.01%68.76%-55173.99%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22
PS Ratio
74819.92108125.08---